• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>other >Characterization of ELISA Detection of Broad-spectrum Anti- Epstein-Barr Virus Antibodies Associated with Nasopharyngeal Carcinoma
【2h】

Characterization of ELISA Detection of Broad-spectrum Anti- Epstein-Barr Virus Antibodies Associated with Nasopharyngeal Carcinoma

机译：与鼻咽癌相关的广谱抗Epstein-BARR病毒抗体的ELISA检测表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Epstein-Barr virus (EBV) infection is associated with undifferentiated nasopharyngeal carcinomas (NPC). A distinct seroreactivity pattern to EBV is predictive of subsequent risk of sporadic and familial nasopharyngeal carcinomas. There are currently no accepted screening tools for guiding the clinical management of individuals at high-risk for nasopharyngeal carcinomas, particularly unaffected relatives from nasopharyngeal carcinoma multiplex families. Therefore, the reproducibility of a panel of largely synthetic peptide-based anti-EBV antibody ELISAs was evaluated and their ability to distinguish nasopharyngeal carcinoma cases from controls was explored. IgG and IgA antibodies against 6 different EBV antigens (10 assays, total) were tested on sera from 97 individuals representing the full spectrum of anti-EBV seroprevalence (i.e., healthy individuals with no known EBV seroreactivity, healthy individuals with known EBV seroreactivity, and nasopharyngeal carcinoma cases). Each specimen was tested in triplicate to assess within-batch and across-batch variation, and the triplicate testing was repeated on two separate days. Reproducibility was assessed by the coefficients of variation (CV) and intraclass correlation coefficients (ICC). All markers were detectable in 17% or more of samples. For all but one marker, the overall, within-batch, and across-batch CVs were below 15%, and the ICCs were above 70% for all but three markers. Sensitivity of these markers to detect prevalent nasopharyngeal carcinomas ranged from 22–100%, and among unaffected controls, most distinguished those with and without known seropositivity. In conclusion, a large number of EBV markers can be measured reliably in serum samples using peptide-based anti-EBV ELISAs.
机译：爱泼斯坦巴尔病毒（EBV）感染与未分化的鼻咽癌（NPC）相关。 EBV的独特血清反应性模式可预测散发性和家族性鼻咽癌的后续风险。目前尚无公认的筛查工具来指导高危人群鼻咽癌患者的临床管理，尤其是来自鼻咽癌多重家族的未受影响亲属。因此，评估了一组主要基于合成肽的抗EBV抗体ELISA的可重复性，并探讨了它们区分鼻咽癌病例与对照的能力。在来自97个代表抗EBV血清学全谱的个体的血清中测试了针对6种不同EBV抗原的IgG和IgA抗体（共10种测定）（即，未知EBV血清反应活性的健康个体，已知EBV血清反应性的健康个体和鼻咽癌病例）。每个样品进行三次重复测试以评估批内和批间变异，并在两天中重复进行三次测试。通过变异系数（CV）和组内相关系数（ICC）评估可重复性。在17％或更多的样品中可检测到所有标记。对于除一个标记之外的所有标记，除三个标记外，所有标记的整体，批次内和批次间CV均低于15％，ICC高于70％。这些标记物检测流行的鼻咽癌的敏感性范围为22–100％，在未受影响的对照中，最能区分血清阳性和阴性的患者。总之，使用基于肽的抗EBV ELISA方法可以可靠地测量血清样品中的大量EBV标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号